The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Results from the ENRICH trial: ibrutinib-rituximab vs R-chemo in older patients with MCL
David Lewis, MD, Plymouth University, Plymouth, UK, shares results from the ENRICH study (ISRCTN11038174), a randomized Phase III trial comparing ibrutinib-rituximab (IR) to rituximab-chemotherapy (R-chemo) in older patients with previously untreated mantle cell lymphoma (MCL). The study found that IR was superior to R-chemo in terms of progression-free survival (PFS), with a hazard ratio of 0.67. Patients in the R-chemo arm had higher rates of hematological toxicity, while those in the IR arm had higher rates of cardiac toxicity. This study demonstrates that IR may be an appropriate treatment option for patients with less proliferative disease, although further research is needed for those with blastoid disease. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
